<DOC>
	<DOCNO>NCT00314795</DOCNO>
	<brief_summary>The purpose study evaluate ability peginesatide increase maintain increase hemoglobin level participant chronic kidney disease ( CKD ) ( either dialysis , receive regular hemodialysis peritoneal dialysis , follow renal transplant ) confirm antibody-mediated pure red cell aplasia ( PRCA ) .</brief_summary>
	<brief_title>Efficacy Safety Peginesatide Treatment Anemia Patients With Chronic Kidney Disease</brief_title>
	<detailed_description>This open-label treatment study ; patient enrol study receive AF37702 Injection . Hematologic data prior treatment AF37702 Injection compare value obtain treatment AF37702 Injection ( see Section 6.2 ) . CKD patient document antibody-mediated PRCA , hemoglobin level &lt; 10 g/dL ( without ESA therapy ) require transfusion maintain hemoglobin level , meet eligibility criterion enrol . It anticipate 40 patient enrolled trial . The first group 5 patient receive start dose 0.05 mg/kg , administer every 4 week ( study , 1 month define 4 week ) . Based assessment dose response initial group 5 patient , recommend start dose subsequent patient increase 0.075 mg/kg . The individual dose AF37702 Injection modify base hemoglobin level . Dose adjustment make order achieve maintain hemoglobin target range 10.0-12.0 g/dL ( see Section 5.4.1 ) . The frequency dosing may decrease dose ultimately discontinue Hgb maintain within target range . Due lack treatment option population , frequent dose justified case suboptimal response . If Investigator determine patient suboptimal response despite dose increase , frequency injection may increase every week , total dose may exceed 0.35 mg/kg every 4 week .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Red-Cell Aplasia , Pure</mesh_term>
	<criteria>Participants confirm antibodymediated PRCA potentially eligible enrollment study . Participants must â‰¥ 18 year old time consent . ESAs must discontinue minimum 1 month prior screen . Participant require periodic transfusion maintain hemoglobin . Hemoglobin &lt; 10 g/dL least 2 measurement participant receive transfusion within past 4 week achieve hemoglobin &gt; 10 g/dL . Confirmation antierythropoietin antibody sample obtain analysis central reference laboratory within 1 month prior baseline . Participants either participant chronic kidney disease yet require renal replacement therapy ( participant dialysis ) , regular hemodialysis peritoneal dialysis , follow renal transplant . Participants may may previously treat immunosuppressive therapy . Premenopausal female ( exception surgically sterile ) must negative pregnancy test screening . Written informed consent must obtain . Participants already successfully another erythropoietic agent . Abnormal bone marrow finding consistent diagnosis myelodysplasia , myeloproliferative disorder , hematologic malignancy evidence metastatic infiltration . Poorly control hypertension . Previous exposure investigational agent within 4 week prior administration study drug plan receipt study period . High likelihood early withdrawal interruption study . Participants refuse give informed consent . Women pregnant , lactate use medically approve birth control . Life expectancy &lt; 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pure red cell aplasia</keyword>
	<keyword>PRCA</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal failure</keyword>
	<keyword>CRF</keyword>
	<keyword>anemia</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
	<keyword>ESA</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>Hb</keyword>
	<keyword>Hgb</keyword>
	<keyword>red blood cell</keyword>
	<keyword>red blood cell production</keyword>
</DOC>